This 3-part activity focuses on several aspects of the management of fibromyalgia. Highlights from the first part of the activity include the potential etiologies of fibromyalgia and tools to assist in the diagnosis of patients with this condition. The various types of pharmacologic and nonpharmacologic therapeutic approaches for fibromyalgia are discussed in the second part of the program. The third part of the activity addresses the treatment of comorbidity in patients with fibromyalgia. It also emphasizes the importance of an interdisciplinary approach for the management of fibromyalgia.

Upon completion of this activity, participants should be better able to:

• Discuss the potential underlying etiologies of fibromyalgia syndrome and assess the current methods used to diagnose this condition
• Analyze and interpret the recent clinical data related to pharmacologic and nonpharmacologic therapies for the treatment of fibromyalgia syndrome
• Propose strategies to manage comorbid conditions in patients with fibromyalgia syndrome

This activity has been designed to meet the educational needs of psychiatrists and other clinicians who provide care for patients with fibromyalgia.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media:

Internet

Release and Expiration Dates:

October 26, 2009 - October 25, 2010

Time to Complete:

45 minutes

Daniel J. Clauw, MD
Professor of Medicine, Division of Rheumatology at the University of Michigan
Director, Chronic Pain and Fatigue Research Center
Director, Michigan Institute for Clinical and Health Research
Associate Dean for Clinical and Translational Research
University of Michigan Medical School
Ann Arbor, Michigan

Daniel J. Clauw, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca, Ltd.; Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Pfizer Inc; and Pierre Fabre Pharmaceuticals Inc.

Philip J. Mease, MD
Clinical Professor
University of Washington School of Medicine
Chief, Rheumatology Clinical Research
Swedish Hospital Medical Center
Seattle, Washington

Philip J. Mease, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Fralex Therapeutics Inc.; Jazz Pharmaceuticals, Inc.; Pfizer Inc; and Wyeth Pharmaceuticals Inc.
Grant/Research Support from Allergan, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Fralex Therapeutics Inc.; Jazz Pharmaceuticals, Inc.; Pfizer Inc; and Wyeth Pharmaceuticals Inc.
Speakers Bureau participant with Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Pfizer Inc; and Wyeth Pharmaceuticals Inc.

Andrew F. Leuchter, MD
Professor, Department of Psychiatry and Biobehavioral Science
David Geffen School of Medicine at UCLA
Director, Laboratory of Brain, Behavior, and Pharmacology
Semel Institute for Neuroscience and Human Behavior at UCLA
Los Angeles, California

Andrew F. Leuchter, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Aspect Medical Systems; AstraZeneca, Ltd.; Eli Lilly and Company; GlaxoSmithKline; MEDACorp; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc; and Takeda Pharmaceuticals North America, Inc.
Grant/Research Support from Aspect Medical Systems; Eli Lilly and Company; MedAvante, Inc.; Merck & Co., Inc.; National Center for Complementary and Alternative Medicine; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Pfizer Inc; VivoMetrics; and Wyeth Pharmaceuticals Inc.
Speakers Bureau participant with Eli Lilly and Company and Wyeth Pharmaceuticals Inc.
Shareholder in Aspect Medical Systems.
Advisory Board for Aspect Medical Systems; AstraZeneca, Ltd.; Eli Lilly and Company; GlaxoSmithKline; MEDACorp; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc; and Takeda Pharmaceuticals North America, Inc.

Edwin Jacobson, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

Edwin Jacobson, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

Ian A. Cook, MD
Joanne & George Miller and Family Professor of Psychiatry
Director, UCLA Depression Research and Clinic Program
Semel Institute for Neuroscience and Human Behavior at UCLA
Los Angeles, California

Ian A. Cook, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Neuronetics, Inc. and Scale Venture Partners.
Grant/Research Support from Aspect Medical Systems; Neuronetics, Inc.; and Sepracor Inc.
Speakers Bureau participant with Wyeth Pharmaceuticals Inc.

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education, Inc.

Kirk A. Tacka, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

This program was developed and reviewed by faculty members of the David Geffen School of Medicine at UCLA. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Institute for Medical Education and the Semel Institute for Neuroscience and Human Behavior at UCLA, in association with PVI, PeerView Institute for Medical Education. The Institute for Medical Education takes responsibility for the content, quality and scientific integrity of this CME activity.

The Institute for Medical Education designates this educational activity for a maximum of 0.75 hour of AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

This activity is supported by an educational grant from